0.17
+2.94%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Integrated Biopharma
From its filings with the US Securities and Exchange Commission
Integrated Biopharma is based in Hillside, New Jersey and is incorporated in Delaware. Its shares trade on OTC under the ticker INBP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported revenue of $43.9m and a net loss of $2.8m. At that date it held total assets of $25.3m and shareholders' equity of $17.7m.
Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States and Luxembourg. The Company was originally incorporated in the state of Delaware on August 31, 1995 under the name Chem International, Inc., on December 5, 2000, changed its name to Integrated Health Technologies, Inc. and, on January 29, 2003, changed its name to Integrated BioPharma, Inc. The Company restated its certificate of incorporation in Delaware in June 2006. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.
The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Business Lines which includes the operations of (i) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfillment services, (ii) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC and the holding entity of the Company and (iii) all other inactive subsidiaries of the Company.
Quoted from its 10-K, filed 25 Sept 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Products
- Listed since
- 30 Oct 1996
- Employees
- 153
- Website
- ibiopharma.com ↗
- Head office
- 225 LONG AVENUE, HILLSIDE, NJ, 07205
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Christina KayCo-Chief Executive Officer, Director, since 1994$343,553
- Mrs. Riva SheppardCo-Chief Executive Officer, Director, since 1991$343,553
- Ms. Dina MasiChief Financial Officer, Senior Vice President, Secretary$357,081
- Mr. Damon DeSantisDirector$20,795
- Mr. William MilmoeDirector$23,795
- Mr. Robert CanarickIndependent Director$23,795
- Mr. Eric FriedmanIndependent Director, since 1996$23,795
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Integrated Biopharma Inc has a strong portfolio of biopharmaceutical products, including a diverse range of nutritional supplements and vitamins. These products are highly regarded for their quality and effectiveness.
- The company has a well-established distribution network, allowing it to reach a wide customer base and expand its market share. This gives Integrated Biopharma Inc a competitive advantage over smaller companies in the industry.
- Integrated Biopharma Inc is known for its research and development capabilities, constantly innovating and introducing new products to meet the evolving needs of consumers. This positions the company as a leader in the biopharmaceutical sector.
Weaknesses
- One of the weaknesses of Integrated Biopharma Inc is its dependence on external suppliers for raw materials. Any disruption in the supply chain could impact the company's production capacity and product availability.
- The company has limited market presence in certain geographical regions, limiting its access to potential customers. This poses a challenge for expanding its global reach and market penetration.
- Integrated Biopharma Inc faces increasing competition from both established pharmaceutical companies and emerging biotech startups. This heightens the pressure to continuously innovate and differentiate its products to maintain a competitive edge.
Opportunities
- The growing trend towards natural and organic products presents an opportunity for Integrated Biopharma Inc to further capitalize on its existing product line of nutritional supplements and vitamins.
- Expanding into new markets, particularly in emerging economies, can open up new revenue streams for Integrated Biopharma Inc. These markets often have a rising middle class with increasing purchasing power and demand for healthcare products.
- The advancements in biotechnology and personalized medicine offer potential for Integrated Biopharma Inc to develop innovative products that cater to specific patient needs. This can enhance the company's market position and profitability.
Threats
- Changing government regulations and policies related to healthcare and pharmaceutical products pose a significant threat to Integrated Biopharma Inc. Compliance with these regulations can be costly and time-consuming.
- The risk of intellectual property infringement and the emergence of generic products can erode Integrated Biopharma Inc's market share and profitability. Protecting its intellectual property rights through patents and trademarks is crucial.
- Economic downturns and fluctuations in exchange rates can impact consumer spending patterns and affect the demand for healthcare products, potentially impacting Integrated Biopharma Inc's sales and revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.